je.st
news
Tag: phase
New Ultra-Low Phase Noise HCMOS VCXO From Crystek Provides -150 dBc/Hz Noise Floor
2015-08-04 07:12:45| rfglobalnet Home Page
Crystek Corporation has launched the CVHD-952, a new Ultra-Low Phase Noise HCMOS Voltage Controlled Crystal Oscillator (VCXO) providing a -150 dBc/Hz typical noise floor. This overall ultra-low phase noise translates to a typical phase jitter of 0.5 psec (12 kHz to 80 MHz).
Tags: floor
phase
noise
phase noise
New Ultra-Low Phase Noise HCMOS VCXO From Crystek Provides -150 dBc/Hz Noise Floor
2015-08-04 07:12:45| wirelessdesignonline News Articles
Crystek Corporation has launched the CVHD-952, a new Ultra-Low Phase Noise HCMOS Voltage Controlled Crystal Oscillator (VCXO) providing a -150 dBc/Hz typical noise floor. This overall ultra-low phase noise translates to a typical phase jitter of 0.5 psec (12 kHz to 80 MHz).
Tags: floor
phase
noise
phase noise
Medivir announces that Janssen has started a phase I study to...
2015-08-03 17:02:50| Appliances - Topix.net
Medivir AB today announces that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has started a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir , on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an open-label, two-group study of simeprevir, odalasvir, a hepatitis C virus NS5A inhibitor, and of AL-335, a nucleotide-based HCV polymerase inhibitor.
In Interim Results from Phase 3 Study, Mercks Investigational Ebola Vaccine Efficacious; Study is Continuing
2015-07-31 14:10:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558orInvestor Contacts:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Oncolytics: An Unheralded Biotech With Promising Phase 2 Results
2015-07-29 04:54:53| Biotech - Topix.net
Oncolytics is currently conducting clinical trials in six of the ten most common cancers diagnosed in men and five of the ten most diagnosed in women. Oncolytics Biotech was founded in 1998 and is located in Calgary, Alberta, CA.
Tags: results
phase
promising
biotech
Sites : [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] next »